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P soriatic arthritis (PsA) is a chronic inflammatory arthropa-thy of unknown etiology [1] that affects as many as one-
third of patients with psoriasis. Together with entero-associated 
arthritis (EA), reactive arthritis (ReA), ankylosing spondylitis 
(AS) and undifferentiated spondyloarthritis (uSpA), it is a 
member of the spondyloarthritis (SpA) family of rheumatic 
diseases [2] whose overlapping features include arthritis of the 
axial skeleton, inflammatory back pain, uveitis, dermatological 
and gastroenterological involvement, and a genetic association 
with human leukocyte antigen (HLA)-B27. It affects men and 
women equally (although the presence of axial disease is three 
times more frequent in men), and appears mainly between 
the ages of 30 and 50 years. Its various manifestations include 
mono-oligoarthritis, an erosive and destructive polyarthritis 
that cannot be distinguished from rheumatoid arthritis, and 
spondyloarthropathy with axial involvement or enthesitis, but 
it is also complicated by comorbidities such as cardiovascular 
and metabolic diseases. 
ETIoPATHoGEnESIS
The etiopathogenesis of PsA is still unclear but involves both 
genetic and environmental factors. Pro-inflammatory cyto-
kines are major mediators of systemic and local inflammation, 
and high interleukin 1 (IL-1), IL-6 and tumor necrosis factor 
(TNF) levels have been observed in psoriatic skin lesions and 
the synovial tissue of patients with rheumatoid arthritis (RA) 
or PsA [3]. The synovial infiltrate associated with both diseases 
has a similar number of fibroblast-like synoviocytes, but the 
synovium of PsA patients is characterized by a less hyperplastic 
lining and fewer monocytes/macrophages [3]. 
Although there are also considerably fewer T cells, T cells 
are probably involved in the pathogenesis of both psoriasis and 
PsA because a subset of specific T cells may be sufficient to 
promote inflammation and regulatory T cells may have anti-
inflammatory effects. A recent study of abatacept (a selective 
inhibitor of T cell activation as a result of its competitive bind-
ing to CD80 or CD86) has shown that it is efficacious for joints 
but has less effect on skin lesions [6]. It is also known that 
T-helper (Th) cells producing IL-17 (Th17 cells, which also 
produce TNF, IL-21 and IL-22) play a role in chronic inflam-
matory conditions and are stimulated by IL-23, which is highly 
expressed in psoriatic plaques [3]. The role of IL-23 in PsA is 
not clear, but the Th17-related cytokines IL-17 and IL-23 are 
expressed in the joints of PsA and RA patients, and ongoing 
clinical studies of the Th17 axis are investigating whether it can 
be used in the treatment of PsA. 
The expression of TNFα, IL-1β, IL-6 and IL-18 is equally 
high in patients with PsA and in those with psoriasis, and pub-
lished data support the view that blocking TNFα together with 
IL-1β, IL-6, IL-18 and IL-23 may be effective in PsA. 
TREATMEnT
Due to the clinical heterogeneity of PsA, selecting the most 
appropriate treatment is a challenge. Some countries have 
published treatment recommendations, as have international 
groups such as the Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis (GRAPPA) and the European 
League Against Rheumatism (EULAR). The GRAPPA recom-
mendations consider five domains (peripheral arthritis, skin 
and nail involvement, enthesitis, dactylitis, axial arthritis) and 
use a grid approach to account for various levels of disease 
activity and severity [4]. The EULAR recommendations use an 
algorithmic approach that mainly considers peripheral arthri-
tis, with dactylitis, enthesitis and skin and nail involvement 
being considered separately [5].
The aims when initiating PsA treatment are to alleviate 
signs and symptoms,	inhibit structural damage, and maxi-
mize the patient’s quality of life. Mild PsA is often successfully 
treated with non-steroidal anti-inflammatory drugs (NSAIDs), 
although local intra-articular injections of corticosteroids may 
be used if only a few  joints are involved. Neither, however, 
inhibit the development of structural joint damage.
PsA treatments have often been borrowed from RA, but 
there is a lack of randomized and controlled trials (RCTs) evalu-
ating the impact of  disease-modifying anti-rheumatic drugs 
(DMARDs) on PsA [6], although the findings of observational 
studies indicate that traditional DMARD therapy has little con-
trol over structural damage. 
psoriatic arthritis (PsA), tumor necrosis factor inhibitors 
(TNFi), ustekinumab, apremilast, interleukin 17 (Il-17) 
inhibitors, rituximab
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• dMARdS
One observational cohort study of 23 patients treated with 
methotrexate (MTX) for 2 years found no reduction in 
radiological progression in comparison with matched con-
trols [7], although other authors have found that the early 
administration of high dose MTX significantly decreases 
actively inflamed joint counts and psoriasis and somewhat 
reduces radiological progression. An open-label study com-
paring MTX with MTX+infliximab in patients with early 
disease observed not only very good joint and skin responses 
in the patients receiving the combination, but also substan-
tial improvements in those receiving MTX alone, which is 
in line with everyday clinical experience. Leflunomide is 
effective, and was formally approved for the treatment of 
PsA in Europe. Cyclosporin can rapidly ameliorate psoriatic 
skin lesions, but there is little evidence that it is effective in 
musculoskeletal disease, and its use is limited by the adverse 
effects of hypertension and renal insufficiency. However, it 
has been used in combination with anti-TNF agents such as 
etanercept [8]. 
• AnTI-TnF dRuGS
A number of studies have shown that PsA patients have high 
TNF levels in synovial fluid and the synovium, and it has been 
demonstrated that all anti-TNF agents slow radiographic pro-
gression and improve the patient’s quality of life [8]. 
TNF inhibitors are effective in joints, skin, enthesitis and 
dactylitis in PsA patients, inhibit structural damage, and sig-
nificantly improve function and quality of life [8], and it is 
presumed that they are as effective in the spine as they are in 
patients with AS. Furthermore, RCTs involving PsA patients 
have shown that they are also effective in reducing active joint 
inflammation and radiographic damage [8]. However, some 
patients with severe PsA are resistant to anti-TNF agents or 
develop adverse events and require alternative treatment. 
• RITuxIMAB
One recent study has shown the presence of B cell lymphoid 
aggregates in PsA synovial tissue, and the partial remission 
of psoriasis has been reported in patients receiving rituximab 
for non-Hodgkin lymphoma [6,9]. Furthermore, Cohen has 
described a case in which rituximab led to a dramatic clinical 
improvement and possible structural effect in a patient with 
severe PsA [6].
A number of small open-label cohorts of PsA patients have 
received rituximab administered with the same regimen as that 
used in RA (two intravenous injections of 1000 mg separated 
by an interval of 2 weeks), some of whom showed a slight 
improvement in joint counts although there was little impact 
on skin lesions. One logical off-label application of rituximab 
would be to treat a patient with PsA and current or recent lym-
phoma in whom other agents are contraindicated. However, 
the possible use of rituximab to treat PsA and psoriasis still 
needs to be confirmed by clinical trials. 
• ToCIlIZuMAB
Tocilizumab is a recombinant humanized monoclonal anti-
body (mAb) that inhibits the signal transduction of IL-6 by 
preventing it from interacting with both the membrane-
expressed receptor and its soluble counterpart. It has been 
approved for the treatment of moderate and severe RA in 
adults who have inadequately responded to or been intoler-
ant of previous DMARD or anti-TNF therapy (in Europe in 
January 2009 and the United States in 2010). Treatment with 
tocilizumab alone or in combination with MTX for 24 weeks 
is superior to MTX alone in reducing disease activity in RA 
patients [6,9,10], and has also been reported to be efficient in 
treating Castleman’s disease, adult-onset Still’s disease, Crohn’s 
disease and juvenile inflammatory arthritis.
However, a pilot study (RCT) of the effects of IL-6 inhibitors 
on PsA did not lead to good results, and a recent case study 
of two patients treated with tocilizumab for 6 months did not 
ameliorate arthritis or the skin lesions, although it did lead to 
a decrease in serum C-reactive protein (CRP) in both patients 
[10]. The tolerability of tocilizumab seems to be acceptable. 
• ABATACEPT 
A phase II placebo-controlled study of the effect	of various 
intravenous doses of abatacept on PsA found that 6 months 
treatment with the RA-labelled dose of 10 mg/kg led to	ACR 
20 responses in 48% of the patients. The clinical response data 
were corroborated by a significant improvement in magnetic 
resonance imaging (MRI) scores, although the improvement 
in the skin lesions was less marked. Nevertheless, the ACR and 
skin responses were maintained in the abatacept-treated group 
after 12 months, and the patients originally receiving placebo 
showed similar responses [6].
• uSTEKInuMAB
Ustekinumab is a fully human mAb that has been approved 
for the treatment of psoriasis and PsA. It blocks the activity of 
p40, a protein subunit shared by IL-12 and IL-23, thus neutral-
izing their biological activity. It has been shown that it decreases 
the mRNA expression of IL-12p40, IL-23p19 and interferon-
gamma (INFγ) in the skin, inhibits IL-12 and IL-23-induced 
INFγ, IL-17A, TNFα, IL-2 and IL-10 secretion, and is generally 
safe and well tolerated.
• Il-17 InHIBIToRS
IL-17, an inflammatory cytokine secreted by Th17 T cells 
and other cells, has been identified in psoriatic plaques and 
inflamed entheses [6]. Three IL-17 inhibitors are currently 
being tested in advanced-phase clinical trials: secukinumab 
and ixekizumab are mAbs against IL-17A, and brodalumab 
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many patients become refractory to	current treatment options 
or develop side effects, it is important to find new and effective 
drugs for the treatment of PsA.
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is a mAb against IL-17 receptor A (IL-17RA). They have all 
been shown to improve skin psoriasis: a phase IIb RCT of 
secukinumab found a psoriasis area severity index (PASI) of 
75 and PASI improvements in respectively 81% and 57% of the 
patients after 12 weeks, compared with 9% for placebo; and a 
randomized dose-finding study of ixekizumab showed signifi-
cant PASI improvements in > 77% of patients compared with 
8% for placebo [6]. Brodalumab has also been studied in PsA: 
subcutaneous doses of 140 mg and 280 mg respectively led to 
12 week ACR 20 responses (36.8% and 39.3% of the patients, 
compared with 18.2% for placebo). However, further longer-
term studies are necessary to define the effects of IL-17 inhibi-
tors on the various manifestations of PsA [6].
• APREMIlAST
Apremilast is an oral phosphodiesterase-4 inhibitor that 
regulates inflammatory mediators. Phosphodiesterase-4, the 
dominant phosphodiesterase expressed in immune cells, 
degrades cyclic AMP (cAMP) into AMP [6]. Thus, its inhibition 
increases intracellular cAMP levels, which can down-regulate 
inflammatory responses by partially inhibiting the expression 
of the inflammatory cytokines IL-12, IL-23, TNFα and IFNγ, 
and increasing the expression of the anti-inflammatory media-
tor IL-10. Apremilast has been used in several studies of PsA 
patients and was shown to be efficacious and well tolerated, with 
minimal effects on any laboratory parameters.
ConCluSIonS 
Although pharmacological treatment often begins with MTX, 
anti-TNF therapies remain the gold standard. However, since 
Alopecia areata (AA) is a common autoimmune disease 
resulting from damage of the hair follicle by T cells. The 
immune pathways required for autoreactive T cell activation 
in AA are not defined, limiting clinical development of ration- 
al targeted therapies. Genome-wide association studies 
(GWAS) implicated ligands for the NKG2D receptor (product 
of the KLRK1 gene) in disease pathogenesis. Xing et al. show 
that cytotoxic CD8+NKG2D+ T cells are both necessary and 
sufficient for the induction of AA in mouse models of disease. 
Global transcriptional profiling of mouse and human AA skin 
revealed gene expression signatures indicative of cytotoxic T 
cell infiltration, an interferon-gamma (IFNγ) response and up-
regulation of several γ-chain (γc) cytokines known to promote 
the activation and survival of IFNγ-producing CD8+NKG2D+ 
effector T cells. Therapeutically, antibody-mediated blockade 
of IFNγ, interleukin-2 (IL-2) or interleukin-15 receptor β (IL-15Rβ) 
prevented disease development, reducing the accumulation 
of CD8+NKG2D+ T cells in the skin and the dermal IFN 
response in a mouse model of AA. Systemically administered 
pharmacological inhibitors of Janus kinase (JAK) family protein 
tyrosine kinases, downstream effectors of the IFNγ and γc 
cytokine receptors, eliminated the IFN signature and prevented 
the development of AA, while topical administration promoted 
hair regrowth and reversed established disease. Notably, 
three patients treated with oral ruxolitinib, an inhibitor of 
JAK1 and JAK2, achieved near-complete hair regrowth within 5 
months of treatment, suggesting the potential clinical utility of 
JAK inhibition in human AA. 
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Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
